Emergence of small interfering RNA-based gene drugs for various diseases

H Kurakula, S Vaishnavi, MY Sharif, S Ellipilli - ACS omega, 2023 - ACS Publications
Small molecule, peptide, and protein-based drugs have been developed over decades to
treat various diseases. The importance of gene therapy as an alternative to traditional drugs …

[HTML][HTML] RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations

CS Nabzdyk, L Pradhan-Nabzdyk… - Journal of Translational …, 2017 - Springer
Background Cardiovascular disease remains a major health care challenge. The knowledge
about the underlying mechanisms of the respective vascular disease etiologies has greatly …

RNA therapeutics in cardiovascular disease

T Lucas, A Bonauer, S Dimmeler - Circulation research, 2018 - Am Heart Assoc
Noncoding RNAs have been shown to exert important physiological and pathophysiological
functions. Various studies suggest that modulating noncoding RNAs may provide a …

Long non-coding RNA therapeutics: recent advances and challenges

A Sangeeth, M Malleswarapu, A Mishra… - Current drug …, 2022 - ingentaconnect.com
The discovery of the roles of RNA other than just as a messenger, such as a ribozyme, and
regulatory RNAs, such as microRNA and long noncoding RNAs, is fascinating. RNA is now …

Emerging drugs in the management of hypertension

JA Whitworth - Expert Opinion on Emerging Drugs, 2003 - Taylor & Francis
Hypertension is a global health problem, affecting developing and developed countries
alike. Most patients with hypertension are undiagnosed, and most diagnosed patients are …

Antisense inhibition of hypertension: a new strategy for renin-angiotensin candidate genes

MI Phillips, D Wielbo, R Gyurko - Kidney international, 1994 - Elsevier
Antisense inhibition of hypertension: A new strategy for renin-angiotensin candidate genes.
There are several ways of experimentally studying the influence of candidate genes on …

[HTML][HTML] Updates in small interfering RNA for the treatment of dyslipidemias

S Carugo, CR Sirtori, G Gelpi, A Corsini… - Current Atherosclerosis …, 2023 - Springer
Abstract Purpose of Review Atherosclerotic cardiovascular disease (ASCVD) is still the
leading cause of death worldwide. Despite excellent pharmacological approaches, clinical …

Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules

K Ramya, R Suresh, HY Kumar, BRP Kumar… - Bioorganic & medicinal …, 2020 - Elsevier
Hypertension is a diverse illness interlinked with cerebral, cardiovascular (CVS) and renal
abnormalities. Presently, the malady is being treated by focusing on Renin-angiotensin …

[HTML][HTML] RNA-based therapy in the management of lipid disorders: a review

DJ Blom, AD Marais, R Moodley… - Lipids in Health and …, 2022 - Springer
This review focuses on antisense oligonucleotides and small interfering ribonucleic acid
therapies approved or under development for the management of lipid disorders. Recent …

RNAi therapies: Expanding applications for extrahepatic diseases and overcoming delivery challenges

JW Lee, MK Shim, H Kim, H Jang, Y Lee… - Advanced Drug Delivery …, 2023 - Elsevier
The era of RNA medicine has become a reality with the success of messenger RNA (mRNA)
vaccines against COVID-19 and the approval of several RNA interference (RNAi) agents in …